YL202 for advanced non‑small cell lung, colorectal, cervical, and other solid tumors

A Multicenter, Open-Label, Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of YL202 in Selected Patients With Advanced Solid Tumors

This trial will try YL202, an antibody‑drug conjugate that targets HER3, in adults with advanced non‑small cell lung, colorectal, cervical, or other metastatic solid tumors who have received one or two prior systemic treatments.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. (Industry-sponsored)
• Drugs / interventions: prednisone
• Locations: 1 site (Changsha, Hunan)
• Trial ID: NCT07202364 on ClinicalTrials.gov

What this trial studies

This is a multicenter, open‑label Phase II study in China testing YL202, an antibody‑drug conjugate that targets the HER3 protein, in patients with selected advanced solid tumors. Adults with confirmed non‑small cell lung cancer, colorectal cancer, cervical cancer, or other measurable extracranial metastatic solid tumors who have had one to two prior systemic therapies and have ECOG performance status 0–1 are eligible. The trial will give YL202 and monitor tumor response, safety events, and pharmacokinetic (PK) behavior, with required archival or fresh tumor tissue for biomarker analysis. Outcomes will focus on anti‑tumor activity, tolerability, and drug levels in the blood.

Who should consider this trial

Good fit: Adults (≥18) in China with advanced non‑small cell lung, colorectal, cervical, or other metastatic solid tumors, ECOG 0–1, one to two prior systemic therapy lines, at least one measurable extracranial lesion, and available tumor tissue are ideal candidates.

Not a fit: Patients with poor performance status (ECOG >1), inadequate organ function, brain‑only metastases, more than two prior systemic therapy lines, or whose tumors lack relevant HER3 expression may be unlikely to benefit.

Why it matters

Potential benefit: If successful, YL202 could shrink tumors or slow disease progression in patients whose cancers express HER3, providing a new treatment option after prior therapies.

How similar studies have performed: Other HER3‑targeting antibody‑drug conjugates have shown promising activity in early trials, so the approach has supportive but not yet definitive clinical evidence.

Eligibility criteria

Inclusion Criteria:

* Subjects must meet all the following criteria to be included in the study:

  1. Subjects who are aware of relevant study information prior to the start of the study, and voluntarily sign and date on the informed consent form (ICF).
  2. Subjects aged ≥18 years at the time of giving informed consent
  3. Body mass index (BMI) within the range of 18 to 32 kg/m2.
  4. Subjects with histologically or cytologically confirmed non-Sq NSCLC/CRC/CC or other advanced solid tumor, and had received 1-2 lines of systemic therapy in the advanced/metastatic setting
  5. There is at least one extracranial measurable lesion as the target lesion per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
  6. Archived or fresh tumor tissue samples are available.
  7. Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
  8. The function of organs and bone marrow meets the requirements within 7 days prior to the first dose
  9. Female subjects of childbearing potential must agree to adopt highly effective contraceptive measures from screening throughout the study period and within at least 6 months after the last dose of the investigational product. Male subjects must agree to adopt highly effective contraceptive measures from screening throughout the study period and within at least 6 months after the last dose of the investigational product.
  10. Expected survival ≥3 months.
  11. Be capable of and willing to comply with the visits and procedures stipulated in the study protocol.

Exclusion criteria

* Subjects who meet any of the following criteria should be excluded from the study:

  1. Prior drug therapy targeting HER3
  2. Previously intolerant to topoisomerase I inhibitors or ADC therapy composed of topoisomerase I inhibitors).
  3. Are participating in another clinical study, unless it is an observational (non-interventional) clinical study or in the follow-up period of an interventional study.
  4. The washout period from the previous anti-tumor therapy is insufficient prior to the first dose of the investigational product.
  5. Patients who received major surgery (excluding diagnostic surgery) within 4 weeks prior to the first dose of the investigational product or those who are expected to receive major surgery during the study.
  6. Prior treatment with allogeneic bone marrow transplantation or solid organ transplantation.
  7. Prior treatment with systemic steroids (prednisone \>10 mg/day or equivalent) or other immunosuppressive treatment within 2 weeks prior to the first dose of the investigational product.
  8. Patients who received any live vaccine within 4 weeks prior to the first dose of the investigational product or those who plan to receive live vaccine during the study period.
  9. Meningeal metastasis or cancerous meningitis.
  10. Brain metastasis or spinal cord compression.
  11. Patients with uncontrolled or clinically significant cardiovascular diseases.
  12. Clinically significant complicated pulmonary disorders.
  13. Medical history of hepatic encephalopathy within 6 months prior to the first dose.
  14. Subjects with active or chronic corneal disorders, or other active eye disorders requiring continuous treatment, or any clinically significant corneal disorders that preclude adequate monitoring of drug-induced keratopathy.
  15. Diagnosed with Gilbert's syndrome.
  16. Significantly symptomatic or unstable pleural effusion, peritoneal effusion, and pericardial effusion, or those requiring repeated drainage.
  17. Medical history of gastrointestinal perforation and/or fistula within 6 months prior to the first dose, or active gastric and duodenal ulcers, ulcerative colitis, or other gastrointestinal diseases that may cause hemorrhage or perforation in the opinion of the investigator.
  18. Serious infection prior to the first dose (National Cancer Institute-Common Terminology Criteria for Adverse Events \[NCI CTCAE\] v5.0 grade ≥3),
  19. Patients with severe coagulopathy or other diseases with evident risk of bleeding.
  20. Patients with uncontrolled diabetes mellitus.
  21. Human immunodeficiency virus (HIV) infection; positive syphilis antibody and a positive titer result.
  22. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
  23. Medical history of any other primary malignancies within 5 years prior to the first dose of the investigational product, except fully resected non-melanoma skin cancer, cured in-situ disease, or other cured solid tumors.
  24. Unresolved toxicity of previous anti-tumor therapy,
  25. History of severe hypersensitivity to inactive ingredients in the drug substance (DS) and drug product (DP) or other monoclonal antibodies.
  26. Lactating women, or women who are confirmed pregnant via a pregnancy test within 3 days prior to the first dose.
  27. Have any diseases, medical conditions, organ system dysfunction, or social conditions that may interfere with the subject ability to sign the ICF, adversely affect the subject ability to cooperate and participate in the study, or affect the interpretation of study results, including but not limited to mental illness or substance/alcohol abuse, in the opinion of the investigator.

Where this trial is running

Changsha, Hunan

• Hunan Provincial Tumor Hospital — Changsha, Hunan, China (Recruiting)

Study contacts

• Study coordinator: yongchang zhang, Ph.D.

Conditions Non Small Cell Lung Cancer; Colorectal Cancer; Cervical Cancer; Locally Advanced or Metastatic Solid Tumors